Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2023—LGC SeraCare announced the availability of its Seraseq FFPE BRCA1/2 LGR Reference Material intended for use with next-generation sequencing assays or amplified nucleic-acid–based methods that identify somatic and germline variants in BRCA1 and BRCA2 genes. The reference material contains 20 DNA variants in the genomic background of GM24385. One 10-μm formalin-fixed, paraffin-embedded curl is provided per vial.
January 2023—Bio-Rad Laboratories has announced that Exact Diagnostics HBV, HCV, and HIV-1 screen controls are available in Europe. The controls are designed to monitor the performance of blood donor screening assays and are calibrated against the Third WHO International Standard for HBV (NIBSC code 10/264) and HIV-1 (10/152) and the Fourth WHO International Standard for HCV (06/102). The products are made of whole viruses in a citrate plasma matrix to ensure lot-to-lot reproducibility, have an 18-month shelf life from date of manufacture when stored at −20°C or below, and are stable for 24 hours when stored at 2° to 8°C.
January 2023—Spot Imaging has introduced three instruments for sample tracking and storage designed to address staffing shortages and storage inefficiencies. BlocDoc automatically captures images of cut blocks and raw slides for electronic sharing and tracking. The PathTracker scans cassettes and slide transport containers in bulk, scanning 150 cassettes in less than 25 seconds, and uploads the information to the PathTracker and laboratory information system. PathArchiv is a file-room sample management system for blocks and slides that can trace samples by case, loan status, location, or age.
January 2023—Thermo Fisher Scientific launched its TrueMark Infectious Disease Research Panels. The analytically sensitive, duplexed TaqMan assays are performed on pre-spotted and dried-down plates that include microorganism‑specific pathogens, using real‑time PCR techniques, which enables rapid and accurate detection for investigating microorganisms that cause respiratory, vaginal, urinary, gastrointestinal, and sexually transmitted diseases. The predefined and customizable panel options allow researchers to choose from more than 90 different bacterial and viral strain assays to generate results within four hours of taking the samples. Testing can be done from nasopharyngeal swabs or nasopharyngeal aspirate; vaginal, genital, and lesion swabs; or urine samples.
January 2023—StatLab has introduced the Quantum S2 automated special staining platform. The 36-slide capacity platform provides automation for more than 25 special stains, including GMS and Warthin-Starry silver stains, and uses MasterTech special stains, which produce bright, crisp, high-clarity stains, the company says.
February 2023—Qiagen announced an exclusive strategic partnership with Helix to advance companion diagnostics for hereditary diseases. Under the agreement, Qiagen will be the exclusive marketing and contracting partner in the United States for Helix’s companion diagnostic services.
January 2023—PerkinElmer announced that the FDA has authorized the marketing of its Eonis SCID-SMA assay kit for in vitro diagnostic use by certified laboratories for the detection of spinal muscular atrophy and severe combined immunodeficiency in newborns. This is the first FDA-authorized assay for SMA screening in newborns in the United States, the company says, and is part of the company’s Eonis platform. The Eonis platform is a robust, flexible system that uses real-time PCR technology to screen for SMA and SCID using a single dried blood spot sample.
January 2023—Roche has entered into a collaboration with Pfizer to help patients access resources and locate information about COVID-19 testing, available treatment options, high-risk factors that increase the chance of progressing to severe COVID-19, and ways to seek timely care. People can learn why early testing is important at symptom onset, which health conditions increase the risk of progressing to severe COVID-19, and what treatment options are available on covid19knowmore.com, a Pfizer website. The Pilot COVID-19 At-Home Test, distributed in the U.S. by Roche and manufactured by SD Biosensor, will include a QR code that directs people to the website.
February 2023—Vistapath has introduced its flagship product, the Sentinel pathology processing platform. The platform uses machine vision combined with artificial intelligence to assess specimens and create a gross report in a few seconds. It consists of the Sentinel module, which measures 17 in. W × 12 in. D × 15 in. H, and the touchscreen, which measures 15 in. W × 8 in. D × 11 in. H.
February 2023—Thermo Fisher Scientific has introduced more than 50 Absolute Q liquid biopsy assays for research use. The wet lab verified liquid biopsy assays provide highly sensitive, specific nucleic acid quantification, enabling single nucleotide polymorphisms detection down to 0.1 percent variant allele frequency.
